Farhat Afrin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9309041/publications.pdf

Version: 2024-02-01

136740 189595 2,644 60 32 50 h-index citations g-index papers 63 63 63 3814 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Mesenchymal stem cellâ€based therapy: a new paradigm in regenerative medicine. Journal of Cellular and Molecular Medicine, 2009, 13, 4385-4402.	1.6	235
2	Mesenchymal Stem Cells: Molecular Targets for Tissue Engineering. Stem Cells and Development, 2007, 16, 7-24.	1.1	157
3	<i>Leishmania</i> Antigens Are Presented to CD8+ T Cells by a Transporter Associated with Antigen Processing-Independent Pathway In Vitro and In Vivo. Journal of Immunology, 2006, 177, 3525-3533.	0.4	130
4	Stromal-Derived Factor-1/ <i>CXCR4</i> Signaling: Indispensable Role in Homing and Engraftment of Hematopoietic Stem Cells in Bone Marrow. Stem Cells and Development, 2011, 20, 933-946.	1.1	115
5	In vitro antifungal activity of hydroxychavicol isolated from Piper betle L. Annals of Clinical Microbiology and Antimicrobials, 2010, 9, 7.	1.7	110
6	Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes. Infection and Immunity, 1997, 65, 2371-2377.	1.0	103
7	Characterization of Leishmania donovani Antigens Encapsulated in Liposomes That Induce Protective Immunity in BALB/c Mice. Infection and Immunity, 2002, 70, 6697-6706.	1.0	100
8	Conditions Influencing the Efficacy of Vaccination with Live Organisms against Leishmania major Infection. Infection and Immunity, 2005, 73, 4714-4722.	1.0	75
9	Therapeutic efficacy of artemisinin-loaded nanoparticles in experimental visceral leishmaniasis. Colloids and Surfaces B: Biointerfaces, 2015, 130, 215-221.	2.5	64
10	Low-dose radiation therapy of cancer: role of immune enhancement. Expert Review of Anticancer Therapy, 2011, 11, 791-802.	1.1	62
11	Nanoliposomal artemisinin for the treatment of murine visceral leishmaniasis. International Journal of Nanomedicine, 2017, Volume 12, 2189-2204.	3.3	60
12	Stem Cell c-KITandHOXB4Genes: Critical Roles and Mechanisms in Self-Renewal, Proliferation, and Differentiation. Stem Cells and Development, 2006, 15, 755-778.	1.1	55
13	High Throughput Transcriptome Profiling of Lithium Stimulated Human Mesenchymal Stem Cells Reveals Priming towards Osteoblastic Lineage. PLoS ONE, 2013, 8, e55769.	1.1	55
14	Differential Decline in <i>Leishmania</i> Membrane Antigen-Specific Immunoglobulin G (IgG), IgM, IgE, and IgG Subclass Antibodies in Indian Kala-Azar Patients after Chemotherapy. Infection and Immunity, 1999, 67, 6663-6669.	1.0	53
15	eNOS allelic variants at the same locus associate with HAPE and adaptation. Thorax, 2004, 59, 1000-1002.	2.7	52
16	Apoptosis-like death in Leishmania donovani promastigotes induced by eugenol-rich oil of Syzygium aromaticum. Journal of Medical Microbiology, 2014, 63, 74-85.	0.7	51
17	Antileishmanial Activities of Stearylamine-Bearing Liposomes. Antimicrobial Agents and Chemotherapy, 2000, 44, 1739-1742.	1.4	48
18	Antigen Requirements for Efficient Priming of CD8+ T Cells by Leishmania major-Infected Dendritic Cells. Infection and Immunity, 2005, 73, 6620-6628.	1.0	48

#	Article	IF	CITATIONS
19	A cyanobacterial serine protease of <i>Plasmodium falciparum</i> is targeted to the apicoplast and plays an important role in its growth and development. Molecular Microbiology, 2010, 77, 873-890.	1.2	48
20	Th1-Biased Immunomodulation and Therapeutic Potential of Artemisia annua in Murine Visceral Leishmaniasis. PLoS Neglected Tropical Diseases, 2015, 9, e3321.	1.3	45
21	Leishmanicidal activities of Artemisia annua leaf essential oil against Visceral Leishmaniasis. Frontiers in Microbiology, 2014, 5, 626.	1.5	44
22	Exploring the Role of Medicinal Plant-Based Immunomodulators for Effective Therapy of Leishmaniasis. Frontiers in Immunology, 2014, 5, 193.	2.2	43
23	Susceptibility to high altitude pulmonary oedema: role of ACE and ET-1 polymorphisms. Thorax, 2006, 61, 1011-1012.	2.7	42
24	Extracts of Artemisia annua leaves and seeds mediate programmed cell death in Leishmania donovani. Journal of Medical Microbiology, 2012, 61, 1709-1718.	0.7	42
25	Infectivity and Virulence of Leishmania donovani Promastigotes+a Role for Media, Source, and Strain of Parasite. Journal of Eukaryotic Microbiology, 2002, 49, 270-274.	0.8	39
26	INDUCTION OF PARTIAL PROTECTION AGAINST LEISHMANIA DONOVANI BY PROMASTIGOTE ANTIGENS IN NEGATIVELY CHARGED LIPOSOMES. Journal of Parasitology, 2000, 86, 730.	0.3	38
27	Immunotherapeutic Potential of Eugenol Emulsion in Experimental Visceral Leishmaniasis. PLoS Neglected Tropical Diseases, 2016, 10, e0005011.	1.3	38
28	Leishmania-Host Interactions—An Epigenetic Paradigm. Frontiers in Immunology, 2019, 10, 492.	2.2	38
29	Immunoglobulin Subclass Distribution and Diagnostic Value of <i>Leishmania donovani </i> Antigen-Specific Immunoglobulin G3 in Indian Kala-Azar Patients. Vaccine Journal, 1999, 6, 231-235.	2.6	36
30	Endothelin-1 gene variants and levels associate with adaptation to hypobaric hypoxia in high-altitude natives. Biochemical and Biophysical Research Communications, 2006, 341, 1218-1224.	1.0	34
31	In vitro antifungal activities of amphotericin B in combination with acteoside, a phenylethanoid glycoside from Colebrookea oppositifolia. Journal of Medical Microbiology, 2011, 60, 1326-1336.	0.7	34
32	Protection of Mice against Visceral Leishmaniasis by Immunization with Promastigote Antigen Incorporated in Liposomes. Journal of Parasitology, 1997, 83, 70.	0.3	33
33	LEISHMANICIDAL ACTIVITY OF STEARYLAMINE-BEARING LIPOSOMES IN VITRO. Journal of Parasitology, 2001, 87, 188-193.	0.3	33
34	Enhanced Antitumor Immunity Contributes to the Radio-Sensitization of Ehrlich Ascites Tumor by the Glycolytic Inhibitor 2-Deoxy-D-Glucose in Mice. PLoS ONE, 2014, 9, e108131.	1,1	33
35	Polarization of macrophages towards M1 phenotype by a combination of 2-deoxy- d -glucose and radiation: Implications for tumor therapy. Immunobiology, 2016, 221, 269-281.	0.8	33
36	Protection from radiation-induced mitochondrial and genomic DNA damage by an extract of Hippophae rhamnoides. Environmental and Molecular Mutagenesis, 2006, 47, 647-656.	0.9	32

#	Article	IF	CITATIONS
37	Radioprotective properties of apple polyphenols: An in vitro study. Molecular and Cellular Biochemistry, 2006, 288, 37-46.	1.4	31
38	Apoptosis mediated leishmanicidal activity of Azadirachta indica bioactive fractions is accompanied by Th1 immunostimulatory potential and therapeutic cure in vivo. Parasites and Vectors, 2015, 8, 183.	1.0	31
39	CYP11B2 gene polymorphisms and hypertension in highlanders accustomed to high salt intake. Journal of Hypertension, 2005, 23, 79-86.	0.3	29
40	A new approach for the delivery of artemisinin: Formulation, characterization, and ex-vivo antileishmanial studies. Journal of Colloid and Interface Science, 2014, 432, 258-269.	5.0	29
41	Leishmanicidal Activity of Piper nigrum Bioactive Fractions is Interceded via Apoptosis In Vitro and Substantiated by Th1 Immunostimulatory Potential In Vivo. Frontiers in Microbiology, 2015, 6, 1368.	1.5	28
42	Predominance of interaction among wild-type alleles of CYP11B2 in Himalayan natives associates with high-altitude adaptation. Biochemical and Biophysical Research Communications, 2006, 348, 735-740.	1.0	25
43	Cinnamomum cassia exhibits antileishmanial activity against Leishmania donovani infection in vitro and in vivo. PLoS Neglected Tropical Diseases, 2019, 13, e0007227.	1.3	24
44	Isolation, characterization and antimicrobial evaluation of a novel compound N-octacosan $7\hat{l}^2$ ol, from Fumaria parviflora Lam. BMC Complementary and Alternative Medicine, 2014, 14, 98.	3.7	23
45	Isotype Profiles of Leishmania donovani-Infected BALB/c Mice: Preferential Stimulation of IgG2a/b by Liposome-Associated Promastigote Antigens. Journal of Parasitology, 1998, 84, 743.	0.3	21
46	Protection of normal cells and tissues during radio- and chemosensitization of tumors by 2-deoxy-D-glucose. Journal of Cancer Research and Therapeutics, 2009, 5, 32.	0.3	18
47	\hat{I}^2 -Nitrostyrenes as Potential Anti-leishmanial Agents. Frontiers in Microbiology, 2016, 7, 1379.	1.5	17
48	Targeting malaria and leishmaniasis: Synthesis and pharmacological evaluation of novel pyrazole-1,3,4-oxadiazole hybrids. Part II. Bioorganic Chemistry, 2019, 89, 102986.	2.0	17
49	Novel RuvB nuclear ATPase is specific to intraerythrocytic mitosis during schizogony of Plasmodium falciparum. Molecular and Biochemical Parasitology, 2012, 185, 58-65.	0.5	16
50	Identification of R2TP complex of Leishmania donovaniand Plasmodium falciparumusing genome wide in-silico analysis. Communicative and Integrative Biology, 2013, 6, e26005.	0.6	14
51	Cytotoxic and radioprotective effects of Podophyllum hexandrum. Environmental Toxicology and Pharmacology, 2006, 22, 113-120.	2.0	12
52	Critical Antileishmanial in vitro Effects of Highly Examined Gold Nanoparticles. International Journal of Nanomedicine, 2021, Volume 16, 7285-7295.	3.3	9
53	Nanomedicines for Therapy of Visceral Leishmaniasis. Journal of Nanoscience and Nanotechnology, 2016, 16, 2143-2151.	0.9	7
54	Antileishmanial Potential of & https://www.comp.com.com.com/stille/samp;gt; amp;lt;i& notential of & notential	0.1	7

#	Article	IF	CITATIONS
55	Transgene expression study of CXCR4 active mutants. Cell Adhesion and Migration, 2014, 8, 384-388.	1.1	5
56	Identification of inhibitors of Plasmodium falciparum RuvB1 helicase using biochemical assays. Protoplasma, 2015, 252, 117-125.	1.0	5
57	Regulated expression of CXCR4 constitutive active mutants revealed the up-modulated chemotaxis and up-regulation of genes crucial for CXCR4 mediated homing and engraftment of hematopoietic stem/progenitor cells. Journal of Stem Cells and Regenerative Medicine, 2013, 9, 19-27.	2.2	4
58	High-Throughput Transcriptome Profiling Of Human Mesenchymal Stem Cells Reveals A Role For Wnt/GSK-3 Signaling In Their Hypoimmunomodulation. Nature Precedings, 2011, , .	0.1	2
59	Conformal Coating (Encapsulation) of Human Single Cells by Biodegradable Chitosan Nanoparticles and Their Response Assessment <i>In Vitro</i> and <i>In Vivo</i> Journal of Nanopharmaceutics and Drug Delivery, 2014, 2, 227-234.	0.3	1
60	Introductory Chapter: Leishmaniasis: An Emerging Clinical Syndrome., 2018,,.		O